Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

R-Biopharm is IVDR certified

PressRelease

R-Biopharm is IVDR certified

PressRelease

Responsabilità editoriale di news aktuell

30 giugno 2022, 11:45

news aktuell

- RIPRODUZIONE RISERVATA

- RIPRODUZIONE RISERVATA

PressRelease - Responsabilità editoriale di news aktuell

The quality management system of the biotechnology company complies with the European in-vitro Diagnostic Regulation (IVDR)

Darmstadt, June 30, 2022 – Quality orientation is an integral part of the culture and processes at R-Biopharm AG. The biotechnology company from southern Hesse thus ensures that quality is integrated throughout the entire company and continually improved in order to deliver reliable products for the health of patients in the long term. The family owned company has regular audits conducted to check the suitability and functionality of all quality-related elements. In fall 2021, R-Biopharm was one of the first companies to undergo the comprehensive audit for the new IVDR certification by TÜV SÜD and has now received the certificate.

What has become mandatory for manufacturers of in vitro diagnostics throughout Europe after a five-year transitional phase at the end of May 2022 in accordance with the European regulation for in vitro diagnostics has already been proven by the biotechnology company in fall 2021. The IVDR certification will ensure that R-Biopharm can continue to offer its clinical in vitro diagnostics in Europe and worldwide according to the stricter legal requirements. The simultaneous recertification according to MDSAP (Medical Device Single Audit Program), ISO 9001:2015, and DIN EN ISO 13485:2016 as well as the Directive for in-vitro diagnostics 98/79/EC makes R-Biopharm one of only few companies worldwide that are currently certified according to these four standards.

With its holistic quality management system, R-Biopharm ensures that normative and regulatory requirements are fulfilled from the development to the application of products and that correspondingly high-quality standards apply. “In our company, quality is not the action of a few but rather the attitude of all our employees”, says board member Dr Hans Frickel. “Our focus on quality is also highly relevant internally. By applying quality-oriented standards, we can detect risks and errors, efficiently design working methods, identify our strengths and potentials, and derive needs for action that will help us to continually improve”.

Press contact:

Simone Feiler

Head of Corporate Brand

Communication

https://r-biopharm.com

https://r-biopharm.com/contact/

https://r-biopharm.com/news-press/download-gallery/

 

R-Biopharm AG

An der neuen Bergstraße 17

64297 Darmstadt, Germany

Tel.: 0 61 51 - 81 02-538

Mobile: 0 160 - 55 273 60

Fax: 0 61 51 - 81 02-40

Email: s.feiler@r-biopharm.de

 

 

 

PressRelease - Responsabilità editoriale di news aktuell

Tutti i Press Release di Economia

Condividi

Guarda anche

O utilizza